Overview

Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-04937319 following multiple (14 days) escalating oral doses in patients with type 2 diabetes.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer